Perimenopause, Menopause and Mental Health: What Nobody Told You to Expect

Photo by Roman Biernacki: https://www.pexels.com/photo/woman-sitting-in-dark-rustic-room-with-basket-29387759/

Nobody warned her about the rage.

She had read about hot flushes, night sweats, irregular periods. She was prepared — or thought she was — for the physical inconvenience of it. What she was not prepared for was the anxiety that arrived without a clear trigger. The low mood that did not respond to the things that had always worked before. The cognitive fog that made her question her competence. And the anger — sudden, disproportionate, directed at people she loved — that frightened her.

She went to her GP. She was told she was probably stressed.

This is not an unusual story. It is, in fact, a remarkably common one.

Up to now, you may have been managing the psychological symptoms of perimenopause or menopause with the tools available to you — attributing them to stress, to workload, to aging, to depression, to anything except the hormonal transition that is actually driving them. But what if there is a better way to understand what is happening?

This article is about the mental health impact of perimenopause and menopause — what it actually is, why it so consistently goes unrecognised, and what the evidence says about managing it effectively.

What perimenopause actually is

Perimenopause is the transitional phase preceding menopause — the point at which twelve consecutive months have passed without a menstrual period. Perimenopause can begin anywhere from two to twelve years before menopause itself, typically starting in the mid-to-late forties, though it can begin earlier. During this phase, oestrogen and progesterone levels fluctuate considerably before their sustained decline. It is this fluctuation — rather than the eventual low stable levels of post-menopause — that is associated with the most significant and unpredictable psychological symptoms (Soares, 2014).

This is a clinically important distinction. Perimenopause is not simply "before menopause." It is a distinct neurobiological period characterised by hormonal instability that affects multiple brain systems simultaneously.

Why the mental health impact is so consistently missed

Perimenopause typically arrives during a decade of life — the mid-forties to mid-fifties — that is, for many women, already saturated with stressors. Career pressures. Caring responsibilities for both children and ageing parents. Relationship transitions. The accumulated load of years of emotional labour. When psychological symptoms emerge in this context, they are almost invariably attributed to the context rather than to the underlying hormonal transition.

The result is a diagnostic pattern that has been documented repeatedly in the literature: perimenopausal women presenting to primary care with anxiety, depression, or cognitive complaints are significantly more likely to receive a psychiatric diagnosis and antidepressant prescription than to receive a hormonal evaluation (Maki et al., 2019). The psychological symptoms are real — but they are being treated without addressing their primary driver.

The second reason is that the symptom profile of perimenopausal mental health disruption does not always resemble textbook depression or anxiety. It is frequently characterised by irritability and rage rather than sadness, by anxiety that arrives without a clear cognitive content, by cognitive changes that are genuinely alarming but do not appear on standard neuropsychological testing, and by a sense of identity disruption that sits alongside rather than within a mood disorder.

The neurobiological basis

Oestrogen is not primarily a reproductive hormone. It is a neuroactive steroid with significant effects across the central nervous system — including effects on serotonin, dopamine, and noradrenaline systems, on the HPA axis stress response, on hippocampal neuroplasticity, and on sleep architecture (Brinton et al., 2015).

During perimenopause, the fluctuation and eventual decline of oestrogen affects all of these systems simultaneously. The practical consequences include:

Mood dysregulation. Oestrogen modulates serotonergic and noradrenergic activity. As levels fluctuate, the neurochemical systems that regulate mood become less stable. Women with no prior history of depression or anxiety can develop significant symptoms during perimenopause; women with prior histories are at considerably elevated risk of recurrence or exacerbation (Freeman et al., 2006).

Anxiety. The HPA axis, which governs the stress response, is modulated by oestrogen. Declining oestrogen is associated with increased cortisol reactivity — a more reactive stress response to smaller triggers — and with elevated baseline anxiety (Gordon et al., 2015).

Cognitive changes. Oestrogen supports hippocampal neuroplasticity and is involved in memory consolidation, verbal fluency, and processing speed. The cognitive changes of perimenopause — frequently described as brain fog, word-finding difficulty, and memory lapses — are well-documented and, for the majority of women, transient rather than progressive (Maki & Henderson, 2016). They are, however, deeply alarming when they occur, particularly for women whose professional identity is closely tied to cognitive performance.

Sleep disruption. Night sweats and vasomotor symptoms disrupt sleep architecture independently of any psychological symptoms. Sleep disruption then compounds mood dysregulation, anxiety, and cognitive impairment — creating a cycle that is difficult to interrupt without addressing the underlying hormonal driver.

Rage and irritability. Perhaps the least discussed and most distressing psychological symptom of perimenopause is the emergence of intense, apparently disproportionate anger. This is not a psychological failure or a character change. It is a neurobiological consequence of oestrogen fluctuation on limbic system regulation and stress reactivity.

The window of vulnerability

Researchers have identified perimenopause as a "window of vulnerability" for mood disorders — a period during which women who would otherwise not develop depression or anxiety are at substantially elevated risk (Soares, 2014). The risk is highest during late perimenopause, when hormonal fluctuation is most pronounced.

A longitudinal study by Freeman et al. (2006) found that women were twice as likely to develop clinically significant depressive symptoms during perimenopause than during the premenopausal period, independent of prior history or psychosocial stressors. This is not a trivial finding. It means that the psychological symptoms of perimenopause are not exclusively a function of the stress of this life stage. They are a function of the neurobiological transition itself.

This distinction matters for treatment. Psychological symptoms that are primarily driven by hormonal fluctuation will have a limited response to psychological intervention alone, and may respond substantially to hormonal management — which is a clinical conversation, not an automatic recommendation, but one that is significantly underoccurring.

What actually helps

Hormonal management. Menopausal hormone therapy (MHT) — previously known as HRT — has a complex public reputation, shaped significantly by a misreported 2002 study whose findings were subsequently substantially revised. The current evidence base supports MHT as the most effective treatment for vasomotor symptoms and associated mood disruption in perimenopausal and early postmenopausal women, and as a reasonable option for psychological symptoms in the absence of contraindications (NICE, 2015). This is a conversation to have with a GP or menopause specialist, not a decision to make from a blog.

Antidepressants. SSRIs and SNRIs have evidence for perimenopausal depression and anxiety independent of their effects on vasomotor symptoms. They are a reasonable option, particularly where MHT is contraindicated or declined. They are not, however, a complete answer where the primary driver is hormonal rather than neurochemical.

Psychological intervention. Cognitive Behavioural Therapy adapted for menopause (CBT-M) has an evidence base for hot flushes, sleep disruption, and mood symptoms (Ayers et al., 2012). More broadly, CBT and ACT are useful for the anxiety and mood symptoms of perimenopause, particularly in combination with hormonal management where appropriate.

Sleep intervention. Given the centrality of sleep disruption to the symptom cascade, directly addressing sleep is a clinical priority rather than a secondary concern. Cognitive Behavioural Therapy for Insomnia (CBT-I) has a strong evidence base and is recommended as a first-line treatment ahead of sleep medication in most clinical guidelines.

Lifestyle factors. Regular aerobic exercise has demonstrated effects on mood, sleep, and vasomotor symptoms in perimenopausal women (Daley et al., 2015). This is not a suggestion to exercise instead of treating the transition medically. It is an adjunct with a meaningful evidence base.

Seeking support — and what to ask for

The most consistent barrier to appropriate care for perimenopausal mental health is not access to services — it is the framing of the consultation. Women who present to primary care with psychological symptoms during this life stage are significantly more likely to receive psychological treatment for those symptoms in isolation than to receive a comprehensive hormonal evaluation alongside it.

If you are in your mid-forties to mid-fifties, experiencing new or worsening psychological symptoms, and have not had a conversation with your GP that includes the word perimenopause — that conversation is worth initiating. Specifically:

• Ask for your symptoms to be considered in the context of hormonal transition, not only in isolation

• Ask for a referral to a menopause specialist if your GP is not confident in this area

• If you are considering MHT, ask for current evidence-based information rather than information based on the 2002 WHI study, which has been substantially revised

You are entitled to a clinical response that addresses the whole picture.

If you are also neurodivergent

For late-diagnosed autistic and ADHD women, perimenopause frequently represents a significant escalation of existing difficulties — and one that is almost entirely absent from clinical guidance.

Oestrogen has a modulating effect on dopamine systems, which are centrally implicated in ADHD. As oestrogen declines, ADHD symptoms that were previously managed — with or without medication — often become significantly more difficult to control. Women who have been functioning adequately with their ADHD diagnosis, or who have been managing without one, may find that perimenopause tips the balance in ways that are alarming and difficult to explain.

For autistic women, the masking effort that perimenopause demands — managing cognitive fog, emotional dysregulation, and sensory changes while maintaining professional and social function — compounds autistic burnout substantially. The hormonal transition removes the neurobiological scaffolding that was supporting the mask.

Late-diagnosed neurodivergent women navigating perimenopause are managing a double transition with clinical guidance designed for neither. Resources specifically for neurodivergent women at midlife are available at Mindpath Academy.

When to seek professional support

The following warrant professional attention:

• New or significantly worsening anxiety or depression in the mid-forties to mid-fifties, regardless of apparent psychosocial triggers

• Cognitive changes that are affecting your professional or personal functioning

• Rage or emotional dysregulation that is frightening you or affecting your relationships

• Sleep disruption lasting more than a few weeks

• A sense that your identity or sense of self is fundamentally destabilised

A GP is the starting point. Ask specifically for perimenopause to be included in the clinical picture. A menopause specialist, a psychiatrist with expertise in reproductive mental health, or a clinical psychologist with experience in this area are appropriate referrals depending on the presentation.

→ Download the free Perimenopause and Mental Health Self-Guide A clinical resource covering what is happening neurobiologically, what helps, and how to have the conversation with your doctor.

→ Book a single coaching session with Dr Melanie du Preez One session. No package required. A space to make sense of what is happening and what your options are.

References

Ayers, B., Smith, M., Hellier, J., Mann, E., & Hunter, M. S. (2012). Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats. Menopause, 19(7), 749–759. https://doi.org/10.1097/gme.0b013e31823fe835

Brinton, R. D., Yao, J., Yin, F., Mack, W. J., & Bhatt, D. L. (2015). Perimenopause as a neurological transition state. Nature Reviews Endocrinology, 11(7), 393–405. https://doi.org/10.1038/nrendo.2015.82

Daley, A., Stokes-Lampard, H., Thomas, A., & MacArthur, C. (2015). Exercise for vasomotor menopausal symptoms. Cochrane Database of Systematic Reviews, 4, CD006108. https://doi.org/10.1002/14651858.CD006108.pub4

Freeman, E. W., Sammel, M. D., Lin, H., & Nelson, D. B. (2006). Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry, 63(4), 375–382. https://doi.org/10.1001/archpsyc.63.4.375

Gordon, J. L., Girdler, S. S., Meltzer-Brody, S. E., Stika, C. S., Thurston, R. C., Clark, C. T., Prairie, B. A., Moses-Kolko, E., Joffe, H., & Wisner, K. L. (2015). Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression. American Journal of Psychiatry, 172(3), 227–236. https://doi.org/10.1176/appi.ajp.2014.14070918

Maki, P. M., & Henderson, V. W. (2016). Cognition and the menopause transition. Menopause, 23(7), 803–805. https://doi.org/10.1097/GME.0000000000000681

Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly, G., Bobo, W. V., Rubin, L. H., Koleva, H. K., Cohen, L. S., & Soares, C. N. (2019). Guidelines for the evaluation and treatment of perimenopausal depression. Menopause, 26(5), 481–498. https://doi.org/10.1097/GME.0000000000001323

NICE. (2015). Menopause: Diagnosis and management (NICE guideline NG23). National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng23

Soares, C. N. (2014). Depression and menopause: Current knowledge and clinical recommendations for a critical window. Psychiatric Clinics of North America, 37(2), 239–254. https://doi.org/10.1016/j.psc.2014.01.007